Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
91
resultados
Última actualización
13/09/2026 [07:01:00]
Resultados 50 a 75 de 91
Resumen de: WO2026165023A1
The present disclosure is directed to antibodies binding to and neutralizing Middle East Respiratory Syndrome-Related Coronavirus (MERS-CoV) and methods for use thereof.
Resumen de: WO2026163027A1
Provided herein is a replication-defective coronavirus having in its genome a modification, wherein the modification results in a reduced expression of the M gene compared to a coronavirus lacking the modification.
Resumen de: WO2026163139A1
The present disclosure relates to the use of β-lactoglobulin in the treatment of a viral condition, wherein β-lactoglobulin is in its native protein state, wherein the viral condition is caused by a human Rotavirus strain or Coronavirus OC43. The present disclosure further relates to a pharmaceutical composition comprising β-lactoglobulin and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition further comprises at least one additional therapeutic agent.
Resumen de: AU2025219283A1
The present disclosure relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Resumen de: AU2025218930A1
The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Resumen de: US20260226425A1
An isolated nucleic acid comprising a recombinant coronavirus genome having a genetic modification that provides cold-adapted growth relative to a parent virus that is not cold-adapted and a vaccine comprising the recombinant genome and methods of using the vaccine are provided.
Resumen de: US20260226140A1
Disclosed are a monoclonal antibody capable of rapidly, simply, and highly sensitively detecting and measuring SARS-CoV-2 contained in a test sample, and an immunoassay method and immunoassay device for SARS-CoV-2 using the same. The monoclonal antibody or its antigen-binding fragment includes heavy chain CDR1-CDR3 having specific amino acid sequences and light chain CDR1-CDR3 having specific amino acid sequences. The immunoassay method for SARS-CoV-2 includes performing an immunoassay of SARS-CoV-2 utilizing an antigen-antibody reaction between this monoclonal antibody or its antigen-binding fragment and SARS-CoV-2 in a sample.
Resumen de: US20260227401A1
Disclosed is a high performance anti-SARS-CoV-2 antibody and a detection reagent using it. The method of detecting SARS-CoV-2 includes detecting SARS-CoV-2 in a sample by an immunoassay method using a monoclonal antibody that specifically reacts with the N protein of SARS-CoV-2, or an antigen-binding fragment thereof. The detection kit for SARS-CoV-2 includes a monoclonal antibody that specifically reacts with the N protein of SARS-CoV-2, or an antigen-binding fragment thereof.
Resumen de: US20260227400A1
0000 Disclosed is a high performance anti-SARS-CoV-2 antibody and a detection reagent using it. The method of detecting SARS-CoV-2 includes detecting SARS-CoV-2 in a sample by an immunoassay method using a monoclonal antibody that specifically reacts with 301aa-319aa, 301aa-320aa, or 351aa-375aa of the amino acid sequence of the N protein of SARS-CoV-2, or an antigen-binding fragment thereof. The detection kit for SARS-CoV-2 includes a monoclonal antibody that specifically reacts with 301aa-319aa, 301aa-320aa, or 351aa-375aa of the amino acid sequence of the N protein of SARS-CoV-2, or an antigen-binding fragment thereof.
Resumen de: US20260227402A1
0000 Disclosed is a high-performance anti-SARS-CoV-2 antibody and a detection reagent using it. The method of detecting SARS-CoV-2 includes detecting SARS-CoV-2 in a sample by an immunoassay method using a monoclonal antibody that specifically reacts with the RNA-binding domain in the N protein of SARS-CoV-2, or an antigen-binding fragment thereof. The detection kit for SARS-CoV-2 includes a monoclonal antibody that specifically reacts with the RNA-binding domain in the N protein of SARS-CoV-2, or an antigen-binding fragment thereof.
Resumen de: US20260226034A1
0000 Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. Sulfone-1H-pyrrole-2-carboxamides of the following formula
0000
0000 inhibit the SARS-CoV-2 PLpro/NSP3 protein and are therefore useful for treating SARS-CoV-2 and COVID-19.
Resumen de: CN122029189A
The present invention provides antibodies that bind to the SARS-CoV-2 spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions and methods of using the above antibodies that bind to the SARS-CoV-2 spike (S) protein.
Resumen de: US20260217840A1
The present invention relates to an antibody specifically binding to an IL-10 receptor and use thereof. The antibody targets IL-10 signaling and has an excellent effect of suppressing cytokine storm and excessive inflammation in severe inflammatory infectious diseases, and in particular, can be effectively used in suppressing inflammatory responses in severe SARS-CoV-2 infection and fatal SFTSV infection.
Resumen de: US20260216194A1
Disclosed herein are methods of treating a taste and smell disorder caused by a viral infection in a subject, comprising administering to the subject a phosphodiesterase inhibitor. Also disclosed herein are methods of treating taste and smell loss from COVID-19 by administering a phosphodiesterase inhibitor to a subject in need thereof.
Resumen de: US20260216253A1
The covid-19 coronavirus has killed more than 5,129,829 people, globally, out of about 255,098,687 infected. About 10 million persons died from cancer in 2020, with 19.3 new cases diagnosed. About 409,000 persons died of malaria in 2019. And none of these diseases made the WHO's list of top 5 deadly diseases of 2019. Modern medicine has made tremendous progress in the prevention and treatment of disease, but the crashing of the covid-19 coronavirus and the extremely high burden of the top deadly diseases point to the urgency of radical and totally disrupting inventions in medicine. Indeed, to effectively overcome the current burden of deadly diseases we need an agile platform with exponentially better efficacy and predictability. The world is in dire need of a new medicine platform that totally and radically disrupts the current healthcare systems and the traditional ways of preventing and treating disease. The present invention does that.The present invention uses transformed microbes, targeted to one or more mucosal surface, to prevent and treat just about any disease of importance. The current means of disease prevention relies on vaccines. As we have seen from countless failures and booster shots, vaccines have extreme limitations and increasingly fewer following. Firstly, vaccine development is unpredictable, lengthy and costly. An important lesson of the covid-19 pandemic is that waiting for several months or years to develop a vaccine, while a disease ravages the popul
Resumen de: AU2026205425A1
Abstract Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating viral disorders and diseases, including symptomatic viral disorders and diseases, including symptomatic COVID-19. 5 Abstract ul b s t r a c t u l
Resumen de: US20260217797A1
Disclosed herein are antibodies that bind to coronavirus spike protein (e.g., SARS-CoV-2 spike protein), and methods of use thereof (e.g., treatment of subjects infected with SARSCoV-2).
Resumen de: ZA202304107B
Disclosed herein is a membrane-based, in-gel loop-mediated isothermal amplification (LAMP) system, kit and method for detection of a target microorganism in a sample suspected of containing the microorganism. LAMP reagents, a lysing agent and a hydrogel are placed together on a filter membrane loaded with a pre-filtered sample. The hydrogel polymerizes over a short time to immobilize any target DNA/RNA particles on the membrane. The system may include a compact, portable device that integrates heat incubation and fluorescence illumination, and also a cloud-based smartphone image analysis application for quantitative results interpretation. If target DNA/RNA are present in the sample, fluorescent amplicons are produced as a result of LAMP reaction. The target microorganisms are detected by visually detecting the presence or absence of the amplicons. The method may be employed for rapid and inexpensive point-of-use (POU) absolute quantification of SARS-CoV-2 in environmental water or wastewater samples with high sensitivity.
Resumen de: US12695826B1
A voice amplifier that amplifies volume of a human voice from a microphone through a mobile device by utilizing a speaker that is communicably connected to the mobile device is disclosed. The voice amplifier is designed for a mobile device, such as a smart phone or a tablet computing device. The voice amplifier purely amplifies the voice from a wired or non-wired microphone through a phone operating system and hardware components and other modules of the mobile device, such as by utilizing the phone speaker and/or an optional wireless or wired speaker. Essentially through a voice amplifier mobile app, a voice can be amplified simply with the touch of one icon. The concept is for people wearing masks due to COVID-19 and future other viruses, and/or dusty, toxic, or otherwise unhealthy air environments where masks are needed, to continue to wear their mask but be able to communicate clearly.
Resumen de: US20260207693A1
0000 An application of Shenling Baizhu in the preparation of a medicine for treating neuropsychiatric symptoms of recovered COVID-19 patients.
Resumen de: US20260209831A1
Methods and systems for detecting the presence of a target nucleic acid sequence in one or more samples of a plurality of samples are described. The methods may comprise the use of linear barcoded nucleic acid probes that, upon hybridization to a target nucleic acid sequence, may be ligated to circularize the probe molecule, amplified, and sequenced. The use of a probe-specific barcode integrated into the nucleic acid probe molecule, and sample-specific barcodes that may be incorporated into the nucleic acid probe molecule or added during the amplification step, enable large-scale multiplexed assay and sample processing.
Resumen de: US20260207714A1
0000 Safe, effective, disease-modifying treatments—and especially, optimized treatments—for Alzheimer's and many other CNS, cardiovascular, metabolic and other disorders remain elusive. This is in part due to many CNS, cardiovascular, metabolic. and other disorders having underlying components on both sides of the blood-brain barrier—e.g., having CNS components as well as cardiovascular and/or metabolic and/or other non-CNS components. Respective examples in CNS, cardiovascular, metabolic and other domains include Alzheimer's disease, heart failure, diabetes and COVID-19. This is in and of itself a challenge, as most drugs (~98% of small molecules; a greater portion of larger molecules such as antibodies and peptides) do not cross the blood brain barrier appreciably, and even when they do, the chances of them having a partition coefficient that optimizes dosing in compartments on both sides of the blood brain barrier is vanishingly low. This invention addresses that challenge with a novel, bicameral, CNS+ (i.e., two-compartment, where one compartment is on the neuronal/glial side of the blood-brain barrier and one compartment is not) approach. This bicameral, CNS+ approach involves parallel 1) Intranasal, direct-to-brain delivery of drugs addressing the CNS component of a CNS, cardiovascular or metabolic disorder 2) Delivery (oral, injection or otherwise) of a cardiovascular &/or metabolic &/or other agent to the central compartment (i.e., blood and well-perfused org
Resumen de: WO2026152199A1
The present invention refers to a novel immunization platform/system and formulation comprising the targets of neutralizing antibodies against respiratory pathogens in the presence or absence of synthetic peptides containing multiple T-cell epitopes from respiratory pathogens, particularly the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein and T cell epitopes of SARS- CoV-2, wherein the immunization platform/system consists of carrier nanoparticles coated with a mucoadhesive polymer (MaP), selected as a delivery vehicle.
Resumen de: WO2026154387A1
Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) contains IgA antibodies against SARS-CoV-2 S glycoproteins. The method includes contacting a biological sample with a SARS-CoV-2 S glycoprotein-coated surface, contacting the surface with a secondary antibody, and detecting the secondary antibody, where if a secondary antibody is detected, the sample contains IgA antibodies against the SARS-CoV-2 S glycoprotein. Assay substrates and kits for performing such methods are also disclosed.
Nº publicación: US20260207540A1 23/07/2026
Solicitante:
CASHMAN DANIEL PATRICK [US]
Cashman Daniel Patrick
Resumen de: US20260207540A1
0000 Pharmaceutical compositions comprising at least one calcium chelating agent such as disodium ethylenediamine tetraacetate (Na2EDTA) as an active pharmaceutical ingredient, are described that are useful for treating an infection by single stranded RNA virus, such as SARS-COV-2, are described. Development of the compositions was assisted by using a novel drug discovery method which utilizes the characterization of a common molecular mechanism in a cohort of an unforeseen clinical co-morbidly patterns identified as outliers. Reverse engineering of the outlier cohort yielded unrecognized calcium requirements for infection by SARS-CoV-2 provided a common molecular mechanism in the outlier group that enabled formulation of the new pharmaceutical compositions.
BOPI
Sede Electrónica
